CJC-1295 is a lab-made drug that raises growth hormone.

Human studies did not test the online claims

CJC-1295 is a peptide made in a lab from protein building blocks. This page shows you the reported harm, hoped-for benefit, and limits of each claim.

People online describe better sleep, easier recovery, less fat, and more energy. They also describe swelling, tingling hands, headaches, tiredness, and blood-sugar changes.

These accounts came from people trying the drug themselves and posting online. A trial with a comparison group did not gather them, so they can't prove the drug caused a change.

Small human studies mainly checked growth hormone and IGF-1, a blood test tied to growth. They didn't test the daily benefits claimed online.

The DAC version uses an extra part to link with a blood protein for days. If an unwanted effect follows, the effect may not fade at once.

Personal reports and study findings do not carry the same weight. Neither kind of evidence gives you a safe use plan or a promise of benefit.

People describe changes that trials haven't checked

These accounts came from public online posts by people trying the drug themselves, not from a controlled study. The source material gave no head count and can't show whether the same person posted more than once.

The hoped-for changes below are personal reports, not trial results.

• Sleep and soreness: Some people said they slept more deeply or felt less sore after training. Better rest or a change in training could explain either report, and no controlled trial tested the claims.

• Waist fat and muscle: Some posts described slow waist-fat loss or a leaner look with less muscle loss. Diet and exercise were happening too, so the posts can't show you whether CJC-1295 caused either change.

• Energy and thinking: Some people described more daytime energy or clearer thinking, often after better sleep. Other people noticed no energy change, and no trial tested an effect on the brain.

• Skin: Some people said their skin felt firmer. A feeling about skin is hard to measure, and no tissue study confirmed the claim.

The unwanted changes below also come from personal reports, not trial results.

• Water, puffiness, and tingling: People described water weight, bloating, a puffy face, and numb or tingling hands. Held water may press on a nerve, and posts often tied these problems to long-form DAC.

• The injection spot and flushing: People named redness, itching, swelling, soreness, or a brief warm head rush. The flushing appeared more in short-form posts, but reports can't show how often either problem occurs.

• Tiredness and headaches: Some people felt tired or sleepy; others described a mild, brief headache. The tiredness conflicts with reports of more energy, which shows how uncertain these accounts are.

• Hunger and blood sugar: Hunger was often reported when ipamorelin, another growth drug, was used too. Other posts mentioned higher blood sugar or poorer insulin control, but no controlled trial produced those claims.

Studies leave several health worries open

No approval for people: Small studies exist, but no major public agency has given the drug approval. No large, long study shows that CJC-1295 is safe or helpful for healthy adults ^{[1] [14]}.

An IGF-1 cancer question remains: Higher IGF-1 results, from a growth blood test, have gone with slightly higher risks for some cancers. The finding does not show that CJC-1295 causes cancer or tell you your own risk ^[9].

The body may hold water: kidneys may keep more salt and water when growth hormone is high. That fits reports of swelling, puffy skin, and tingling when fluid puts pressure on a nerve ^[15].

Blood-sugar control is not settled: A short study of tesamorelin, a related growth drug, raised growth hormone and IGF-1 without a clear loss of blood-sugar control. The brief result cannot settle the risk from longer use ^[16].

The body's defenses may react: FDA papers raised this worry when CJC-1295 was kept off the 503A list of bulk ingredients allowed for certain pharmacies. A newer review calls it a concern, not a proved result ^{[10] [12]}.

The company study stopped: The DAC version reached Phase 2, a middle-stage study, among patients with HIV and fat stored deep in the belly. A patient died, but public papers do not link CJC-1295 with the death ^[7].

The two versions differ: DAC links with albumin, a protein carried in blood, and remains active for days. Modified GRF 1-29 cannot make that link and leaves sooner ^{[2] [11]}.

Sport has a firm rule: The World Anti-Doping Agency bars the drug throughout the year under S2, its group for growth drugs. A failed test can end your right to compete, apart from any health risk ^[17].